Percutaneous Transcatheter Genicular Embolization in Osteoarthritis
Key facts
- Where
- Ústí nad Labem, CzechiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07361198, who can take part
Where in Czechia
- Masarykova nemocnice v Usti nad LabemÚstí nad Labem, CzechiaContact: Pavol ViglášTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
- Trial code
- NCT07361198
- Record updated
- 4 February 2026
- Original description
This clinical study investigates a minimally invasive treatment called percutaneous transcatheter embolization of knee arteries for patients with chronic knee pain caused by advanced knee osteoarthritis or persistent pain after total knee replacement. Osteoarthritis of the knee is a common degenerative condition that can lead to long-term pain, reduced mobility, and decreased quality of life, and some patients do not achieve sufficient relief with standard treatments.Read full original descriptionShow less
This clinical study investigates a minimally invasive treatment called percutaneous transcatheter embolization of knee arteries for patients with chronic knee pain caused by advanced knee osteoarthritis or persistent pain after total knee replacement. Osteoarthritis of the knee is a common degenerative condition that can lead to long-term pain, reduced mobility, and decreased quality of life, and some patients do not achieve sufficient relief with standard treatments.
The study is based on the hypothesis that targeted embolization of small arteries supplying the inflamed tissues of the knee can safely reduce abnormal blood flow associated with inflammation, leading to pain relief and improved knee function. During the procedure, a thin catheter is guided through the blood vessels to the affected area of the knee, where a temporary embolic agent is administered to reduce pathological blood supply.
The aim of the study is to evaluate the safety and effectiveness of this procedure by assessing changes in pain intensity, knee function, and quality of life over a follow-up period of up to 24 months. The results of this study may help determine whether this minimally invasive approach can offer a new treatment option for patients who have limited alternatives for managing chronic knee pain
Inclusion: Adults aged 40 to 80 years; Clinical symptoms consistent with chronic knee pain; Radiographically confirmed knee osteoarthritis of Kellgren-Lawrence grade II-IV or persistent knee pain following total knee arthroplasty; Insufficient pain relief after standard conservative treatment (e.g., pharmacological therapy, physical therapy, or injections); Ability to understand the study procedures and provide written informed consent _ Willingness and ability to comply with the study procedures and follow-up schedule.
Exclusion: Active local or systemic infection; Known coagulation disorders or ongoing anticoagulation that cannot be safely interrupted; Significant peripheral arterial disease affecting the lower limbs; Known allergy or contraindication to iodinated contrast agents; Severe renal impairment; History of fibromyalgia or other generalized chronic pain syndromes that may confound pain assessment; Pregnancy or breastfeeding.